Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluoride SCHEMBL11256207 | 0.86 | TP53 (0.36) | TP53 | |
| SCHEMBL23241046 | 0.76 | TP53 (0.33) | TP53 | |
| SCHEMBL26029528 | 0.76 | TP53 (0.33) | TP53 | |
| SCHEMBL22539871 | 0.74 | ALDH1A1 (0.36) | ALDH1A1SMN1; SMN2ACHETP53MGLL | |
| SCHEMBL26469125 | 0.74 | KDM4E (0.33) | TP53 | |
| SCHEMBL19773458 | 0.72 | CYP2A13 (0.38) | ALDH1A1CYP2A13HPGDSMN1; SMN2ACHE | |
| SCHEMBL25702322 | 0.69 | HSD11B1 (0.32) | ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL16221528 | 0.68 | ALDH1A1 (0.48) | ALDH1A1CYP2A13HPGDSMN1; SMN2ACHE | |
| SCHEMBL18922372 | 0.68 | SMN1; SMN2 (0.32) | ALDH1A1CYP2A13HPGDSMN1; SMN2GAA | |
| SCHEMBL16840093 | 0.67 | CYP2A13 (0.59) | ALDH1A1CYP2A13HPGDSMN1; SMN2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250070-A1 | DIHYDROOXAZOLE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY | AC IMMUNE SA (CH) | 2023-08-10 | — | — | US | disclosed |
| EP-0980374-B1 | PHOSPHODIESTERASE 4-INHIBITING DIAZEPINOINDOLONES | PFIZER HOLDING FRANCE (FR) | 2003-02-12 | — | — | EP | disclosed |
| US-6239130-B1 | ASTHMA, ATOPIC DERMATITIS, RHEUMATOID ARTHRITIS, INFLAMMATORY BOWEL DISORDERS, PULMONARY HYPERTENSION, LIVER INJURY, BONE LOSS, SEPTIC SHOCK, OR MULTIPLE SCLEROSIS, | WARNER-LAMBERT COMPANY | 2001-05-29 | — | — | US | disclosed |
| EP-0980374-A1 | PHOSPHODIESTERASE 4-INHIBITING DIAZEPINOINDOLONES | PARKE-DAVIS (FR) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998049169-A1 | PHOSPHODIESTERASE 4-INHIBITING DIAZEPINOINDOLONES | PARKE-DAVIS (FR) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250070-A1 | DIHYDROOXAZOLE AND THIOUREA DERIVATIVES MODULATING THE NLRP3 INFLAMMASOME PATHWAY | NLRP3, NOD1, NLRP1 | ALDH1A1 570/4885CYP2A13 2598/4885HPGD 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.